Summary & Overview

HCPCS J0218: Injection, olipudase alfa, 1 mg

HCPCS Level II code J0218 denotes the injectable biologic olipudase alfa, billed per 1 mg unit. This code is used for therapeutic enzyme replacement administered in clinical infusion or outpatient settings and is significant nationally due to the high-cost nature and specialized administration requirements of enzyme replacement therapies. Payers nationally manage coverage and utilization of such biologics through medical benefit pathways.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for olipudase alfa, payer coverage landscape, and operational benchmarks relevant to billing and claims processing. The publication summarizes how J0218 is applied in practice, typical sites of service, and the implications for medical billing workflows.

The content covers billing benchmarks, coding considerations, and relevant policy updates that affect reimbursement and prior authorization processes for high-cost infused biologics. Clinical context explains the role of olipudase alfa as enzyme replacement therapy and typical administration settings. Data not provided in the input (such as associated ICD-10 codes, taxonomies, and related codes) is noted as unavailable where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0218HCPCS Level IIolipudase alfaenzyme replacement therapyinfusion servicesmedical billingdrug unit codeoutpatient infusionbiologic therapy

Billing Code Overview

HCPCS Level II code J0218 represents an injectable biologic medication: injection, olipudase alfa-rpcp, 1 mg. The service type is therapeutic enzyme replacement therapy administered by injection, reflecting treatment with olipudase alfa for identified enzyme deficiency disorders. The typical site of service is an infusion or outpatient clinic where parenteral biologic therapies are administered.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A patient with confirmed acid sphingomyelinase deficiency (ASMD; Niemann–Pick disease type B or types A/B) presents to an outpatient infusion center for enzyme replacement therapy. The clinic visit is scheduled for administration of J0218 (olipudase alfa-rpcp) per the treating metabolic specialist's order. Prior to infusion, nursing performs pre-infusion assessment including vital signs, focused review of organomegaly and pulmonary status, and confirms baseline laboratory results (complete blood count, liver function tests, coagulation profile) and any weight-based dosing calculations. An infusion nurse establishes intravenous access, programs the infusion pump, and monitors the patient for infusion-related reactions. The metabolic specialist or supervising physician documents the indication, informed consent, dose administered in milligrams, lot number, and any premedication (antipyretic, antihistamine, corticosteroid) given for reaction prophylaxis. Post-infusion observation occurs per protocol to monitor for delayed hypersensitivity or hemodynamic changes. If an adverse reaction occurs requiring a higher level of care, transfer to an emergency department or observation unit is arranged and appropriate modifiers are applied for billing documentation.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard claim submission	Use when no special circumstance applies to the service.
`22`	Increased procedural services	Use when a significantly greater service is provided (e.g., unusually prolonged infusion with extra documented work).
`23`	Unusual anesthesia — not used for this drug infusion typically	Rarely used; only if unusual anesthesia was required for the infusion procedure.
`52`	Reduced services	Use when the infusion is partially reduced or discontinued for clinical reasons.
`53`	Discontinued procedure	Use when the infusion is started but terminated due to patient condition or reaction.
`54`	Surgical care only — not typically applicable	Not commonly used for outpatient infusions; reserved for surgical global period scenarios.
`55`	Postoperative management only — not typically applicable	Not commonly used for infusion services.
`56`	Preoperative management only — not typically applicable	Not applicable for routine infusions.
`62`	Two surgeons — not applicable	Not applicable to infusion administration.
`78`	Return to operating/procedure room for related procedure during postoperative period	Use only if a related procedure is required emergently after initial infusion visit.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery — not typical	Generally not used for infusion administrations.
`CO`	Services related to a workers' compensation claim	Use when the infusion is billed under workers' compensation.
`CQ`	Service furnished by a registered dietitian or nutrition professional — not typical	Not applicable for infusion administration.
`FX`	Service related to the Indian Health Service or tribal facility	Use when patient receives service in those settings.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Internal Medicine	Metabolic disorders and coordination of chronic infusion therapy.
`2080P0208X`	Medical Genetics	Diagnosis and management of inherited metabolic conditions like ASMD.
`363LP0808X`	Pediatric Hematology-Oncology	Pediatric management when enzyme replacement therapy is delivered to children.
`2084P0800X`	Pediatric Medicine	Pediatric primary care coordination and follow-up for therapeutic infusions.
`372500000X`	Hospitalist	Inpatient admission and management if infusion-related complications require hospitalization.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E75.241`	Niemann-Pick disease type A	ASMD-related diagnosis for which enzyme replacement therapy may be considered in certain clinical contexts.
`E75.242`	Niemann-Pick disease type B	Classic adult/chronic form of acid sphingomyelinase deficiency treated with olipudase alfa.
`E75.243`	Niemann-Pick disease type A/B	Intermediate phenotype; olipudase alfa may be indicated depending on clinical trial/label.
`E75.249`	Niemann-Pick disease, unspecified	Use when subtype is not specified but ASMD is the clinical reason for therapy.
`E83.00`	Disorder of sphingolipid metabolism, unspecified	Broad code for sphingolipid metabolism disorders relevant to enzyme replacement therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly used for initial portion of an infusion visit when olipudase alfa is administered and the infusion duration fits the code's time frame.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)	Used for each additional hour of infusion time beyond the first hour when infusion duration is extended.
`96367`	Intravenous infusion, additional sequential infusion of a new drug/biologic, up to 1 hour	Used if an additional compatible medication or biologic is administered sequentially during the same visit.
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	Used if a bolus medication (e.g., premedication) is administered by IV push during the infusion visit.
`36415`	Collection of venous blood by venipuncture	Used for pre-infusion or monitoring laboratory blood draws associated with the infusion visit.